PTHS (Pelthos Therapeutics) ROE % Adjusted to Book Value: -54.81% (As of Mar. 2026)


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $29.03
! 5 Warning Signs
View Full Analysis

What is Pelthos Therapeutics ROE % Adjusted to Book Value?

Pelthos Therapeutics PTHS -0.62% 8 ROE % Adjusted to Book Value is -54.81% as of Mar. 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 5 warning signs investors should review.

Pelthos Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -110.71%. Pelthos Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 2.02. Pelthos Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -54.81%.

Pelthos Therapeutics ROE % Adjusted to Book Value Related Terms

Pelthos Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Pelthos Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pelthos Therapeutics ROE % Adjusted to Book Value Chart

Pelthos Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -92.85

Pelthos Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -168.44 -69.16 -54.81

PTHS vs CGTX, BDTX, CBUS: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Pelthos Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pelthos Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pelthos Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Pelthos Therapeutics's ROE % Adjusted to Book Value falls into.


PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pelthos Therapeutics ROE % Adjusted to Book Value Calculation

Pelthos Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-239.55% / 2.58
=-92.85%

Pelthos Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-110.71% / 2.02
=-54.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -54.81% mean?
Pelthos Therapeutics (PTHS) has a ROE % Adjusted to Book Value of -54.81% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pelthos Therapeutics and its competitors.
Is Pelthos Therapeutics' ROE % Adjusted to Book Value too high?
Pelthos Therapeutics' current ROE % Adjusted to Book Value is -54.81%. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' ROE % Adjusted to Book Value compare to CGTX and BDTX?
Pelthos Therapeutics' ROE % Adjusted to Book Value of -54.81% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Pelthos Therapeutics and its competitors. Pelthos Therapeutics's current ROE % Adjusted to Book Value is -54.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current ROE % Adjusted to Book Value of -54.81%. The current ROE % Adjusted to Book Value is -54.81%. Pelthos Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current ROE % Adjusted to Book Value is -54.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.03
Price